According to the Complaint, Immunomedics, Inc. purports to be a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts.

On September 10, 2019, the Court issued an Order consolidating cases and appointing co-lead Plaintiffs and co-lead Counsel. Lead Plaintiffs filed a consolidated Complaint on November 18. Defendants filed a Motion to Dismiss the consolidated Complaint on January 17, 2020. On July 31, 2020, the Court denied the Defendants' Motion to Dismiss.

Lead Plaintiffs filed an amended Complaint on July 19, 2021.

On January 20, 2023, the parties entered into a Stipulation of Settlement. The Court granted preliminary approval of the Settlement on February 23. On June 15, the Court granted final approval of the Settlement, including an award of Attorneys’ Fees and Expenses, and entered Final Judgment.